RT Journal Article
SR Electronic
T1 Spatial Profiling of Lung SARS-CoV-2 and Influenza Virus Infection Dissects Virus-Specific Host Responses and Gene Signatures
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.04.20225557
DO 10.1101/2020.11.04.20225557
A1 Kulasinghe, Arutha
A1 Tan, Chin Wee
A1 dos Santos Miggiolaro, Anna Flavia Ribeiro
A1 Monkman, James
A1 Bhuva, Dharmesh
A1 Motta Junior, Jarbas da Silva
A1 Vaz de Paula, Caroline Busatta
A1 Nagashima, Seigo
A1 Baena, Cristina Pellegrino
A1 Souza-Fonseca-Guimaraes, Paulo
A1 de Noronha, Lucia
A1 McCulloch, Timothy
A1 Rossi, Gustavo Rodrigues
A1 Cooper, Caroline
A1 Tang, Benjamin
A1 Short, Kirsty R.
A1 Davis, Melissa J
A1 Souza-Fonseca-Guimaraes, Fernando
A1 Belz, Gabrielle T.
A1 O’Byrne, Ken
YR 2020
UL http://medrxiv.org/content/early/2020/11/06/2020.11.04.20225557.abstract
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in late 2019 has spread globally, causing a pandemic of respiratory illness designated coronavirus disease 2019 (COVID-19). Robust blood biomarkers that reflect tissue damage are urgently needed to better stratify and triage infected patients. Here, we use spatial transcriptomics to generate an in-depth picture of the pulmonary transcriptional landscape of COVID-19 (10 patients), pandemic H1N1 (pH1N1) influenza (5) and uninfected control patients (4). Host transcriptomics showed a significant upregulation of genes associated with inflammation, type I interferon production, coagulation and angiogenesis in the lungs of COVID-19 patients compared to non-infected controls. SARS-CoV-2 was non-uniformly distributed in lungs with few areas of high viral load and these were largely only associated with an increased type I interferon response. A very limited number of genes were differentially expressed between the lungs of influenza and COVID-19 patients. Specific interferon-associated genes (including IFI27) were identified as candidate novel biomarkers for COVID-19 differentiating this COVID-19 from influenza. Collectively, these data demonstrate that spatial transcriptomics is a powerful tool to identify novel gene signatures within tissues, offering new insights into the pathogenesis of SARS-COV-2 to aid in patient triage and treatment.Competing Interest StatementFernando Souza-Fonseca-Guimaraes is a consultant for Biotheus Inc. However, all opinions and reviews presented in this manuscript belong to the authors alone and are independent of the relationships with Biotheus. Other authors declare no competing interests.Funding StatementThis work was supported by grants and fellowships from the National Health and Medical Research Council (NHMRC) of Australia (1157741 AK; 1135898 GTB, 1140406 FSFG), Priority driven Collaborative Cancer Research Scheme, funded by Cure Cancer Australia with the assistance of Cancer Australia and the Can Too Foundation (1182179 AK; 1158085 FSFG), Princess Alexandra Research Foundation (KOB), University of Queensland (GTB, FSFG), Queensland University of Technology (AK), The Garnett Passe and Rodney Williams Memorial Foundation (AK), Walter and Eliza Hall Institute of Medical Research (CT, DB, and MJD). MJD is supported by the Betty Smyth Centenary Fellowship in Bioinformatics. DB is supported by a Chan Zuckerberg Initiative Program grant awarded to G. Smyth.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Autopsy and biopsy materials were obtained from the Pontificia Universidade Catolica do Parana PUCPR the National Commission for Research Ethics (CONEP) under ethics approval numbers 2020001792/30188020.7.1001.0020 and 2020001934/30822820.8.000.0020. The study was also approved under University of Queensland Human Research Ethics Committee (HREC) ratification.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNanostring data that support the findings of this study will be deposited with the Gene Expression Omnibus (GEO) repository and made available onpublication. All the data to eval uate the conclusions in this paper are present either in the main text or in supplementary materials.